bluebird's five-year pricing model for LentiGlobin could resonate with payers

A potential outcomes-based pricing scheme from bluebird bio Inc. (NASDAQ:BLUE) for its gene therapy could resonate with payers and proffer tentative solutions for navigating challenges around outcome tracking, patient portability and the Medicaid best price rule.

Under the model, presented Tuesday at the J.P. Morgan Healthcare Conference, payers would make up to five equal payments for LentiGlobin BB305 across five years, with 80% of the

Read the full 645 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE